GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TScan Therapeutics Inc (NAS:TCRX) » Definitions » Beneish M-Score

TScan Therapeutics (TScan Therapeutics) Beneish M-Score : -2.45 (As of Apr. 29, 2024)


View and export this data going back to 2021. Start your Free Trial

What is TScan Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.45 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for TScan Therapeutics's Beneish M-Score or its related term are showing as below:

TCRX' s Beneish M-Score Range Over the Past 10 Years
Min: -2.91   Med: -2.45   Max: 5.61
Current: -2.45

During the past 5 years, the highest Beneish M-Score of TScan Therapeutics was 5.61. The lowest was -2.91. And the median was -2.45.


TScan Therapeutics Beneish M-Score Historical Data

The historical data trend for TScan Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TScan Therapeutics Beneish M-Score Chart

TScan Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - 5.61 -2.91 -2.45

TScan Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.91 -2.97 -2.83 -2.93 -2.45

Competitive Comparison of TScan Therapeutics's Beneish M-Score

For the Biotechnology subindustry, TScan Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TScan Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TScan Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where TScan Therapeutics's Beneish M-Score falls into.



TScan Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of TScan Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1+0.528 * 1+0.404 * 0.8478+0.892 * 1.5552+0.115 * 0.9873
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8327+4.679 * -0.10237-0.327 * 0.8494
=-2.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $0.00 Mil.
Revenue was 7.211 + 3.887 + 3.148 + 6.803 = $21.05 Mil.
Gross Profit was 7.211 + 3.887 + 3.148 + 6.803 = $21.05 Mil.
Total Current Assets was $194.24 Mil.
Total Assets was $272.15 Mil.
Property, Plant and Equipment(Net PPE) was $71.23 Mil.
Depreciation, Depletion and Amortization(DDA) was $5.36 Mil.
Selling, General, & Admin. Expense(SGA) was $26.35 Mil.
Total Current Liabilities was $29.82 Mil.
Long-Term Debt & Capital Lease Obligation was $85.84 Mil.
Net Income was -19.613 + -22.997 + -24.045 + -22.563 = $-89.22 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0.00 Mil.
Cash Flow from Operations was -23.766 + 8.017 + -22.022 + -23.587 = $-61.36 Mil.
Total Receivables was $0.00 Mil.
Revenue was 3.095 + 3.363 + 4.056 + 3.021 = $13.54 Mil.
Gross Profit was 3.095 + 3.363 + 4.056 + 3.021 = $13.54 Mil.
Total Current Assets was $124.13 Mil.
Total Assets was $199.09 Mil.
Property, Plant and Equipment(Net PPE) was $69.20 Mil.
Depreciation, Depletion and Amortization(DDA) was $5.14 Mil.
Selling, General, & Admin. Expense(SGA) was $20.35 Mil.
Total Current Liabilities was $17.31 Mil.
Long-Term Debt & Capital Lease Obligation was $82.30 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 21.049) / (0 / 13.535)
=0 / 0
=1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(13.535 / 13.535) / (21.049 / 21.049)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (194.237 + 71.234) / 272.149) / (1 - (124.127 + 69.202) / 199.091)
=0.024538 / 0.028942
=0.8478

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=21.049 / 13.535
=1.5552

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(5.137 / (5.137 + 69.202)) / (5.361 / (5.361 + 71.234))
=0.069102 / 0.069992
=0.9873

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(26.354 / 21.049) / (20.352 / 13.535)
=1.252031 / 1.503657
=0.8327

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((85.84 + 29.82) / 272.149) / ((82.303 + 17.305) / 199.091)
=0.424988 / 0.500314
=0.8494

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-89.218 - 0 - -61.358) / 272.149
=-0.10237

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

TScan Therapeutics has a M-score of -2.45 suggests that the company is unlikely to be a manipulator.


TScan Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of TScan Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


TScan Therapeutics (TScan Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
830 Winter Street, Waltham, MA, USA, 02451
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Executives
Timothy J Barberich director 40 ELM ST, CONCORD MA 01752
Barbara Klencke director C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Leiden Dworak officer: Chief Accounting Officer C/O TSCAN THERAPEUTICS, INC., 880 WINTER STREET, WALTHAM MA 02451
Lynx1 Capital Management Lp 10 percent owner 151 CALLE DE SAN FRANCISCO, SUITE 200 PMB 1237, SAN JUAN PR 00901-1607
Weston Nichols 10 percent owner C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Brian M. Silver officer: Chief Financial Officer C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Debora Barton officer: Chief Medical Officer C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
David P Southwell director, officer: Chief Executive Officer C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014